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Purpose: With a growing elderly population, elderly patients with head and neck cancers
represent an increasing challenge with limited prospective data to guide management.
The complex interplay between advanced age, associated co-morbidities, and conventional
local therapies, such as surgery and external beam radiotherapy± chemotherapy, can sig-
nificantly impact elderly patients’ quality of life (QoL). Stereotactic body radiotherapy (SBRT)
is a well-established curative strategy for medical-inoperable early-stage lung cancers even
in elderly populations; however, there is limited data examining SBRT as primary therapy
in head and neck cancer.
Material/methods: Twelve patients with medically inoperable head and neck cancer
treated with SBRT± cetuximab from 2002 to 2013 were retrospectively reviewed. SBRT
consisted of primarily 44 Gy in five fractions delivered on alternating days over 1–2 weeks.
Concurrent cetuximab was administered at a dose of 400 mg/m2 on day
2
−7 followed by
250 mg/m on day 0 and +7 in n=3 (25%). Patient-reported quality of life (PRQoL) was
prospectively recorded using the previously validated University of Washington quality of
life revised (UW-QoL-R).
Results: Median clinical follow-up was 6 months (range: 0.5–29 months). The 1-year actu-
arial local progression-free survival, distant progression-free survival, progression-free
survival, and overall survival for definitively treated patients were 69, 100, 69, and 64%,
respectively. One patient (8%) experienced acute grade 3 dysphagia and one patient
(8%) experienced late grade 3 mucositis; there were no grade 4–5 toxicities. Prospective
collection of PRQoL as assessed by UW-QoL-R was preserved across domains.
Conclusion: Stereotactic body radiotherapy shows encouraging survival and relatively low
toxicity in elderly patients with unresectable head and neck cancer, which may provide an
aggressive potentially curative local therapy while maintaining QoL.
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INTRODUCTION
With a growing elderly population expected to exceed 80,000,000
in the United States by the year 2050, the incidence of elderly
patients with head and neck cancers is similarly expected to dras-
tically increase with a projected incidence over 31,000 by the
year 2030 (1, 2). Elderly patients with head and neck cancers
represent a clinical challenge with limited prospective data to
guide management, as patients over 65–70 are often excluded
from the randomized trials that shape management (3). Elderly
patients more commonly present with locally advanced disease
with less neck involvement, highlighting the potential opportunity
of aggressive local therapy (4, 5). However, the complex interplay
between advanced age, associated co-morbidities, and conven-
tional local therapies such as surgery and external beam radio-
therapy± chemotherapy, can carry significant impact on elderly
patients’ quality of life (QoL) (6). Increasing age and co-morbidity
can increase risks of treatment-related complications and compro-
mise outcomes. The potential negative impact of increasing age
on treatment outcomes was well delineated in the MACH meta-
analysis, where chemotherapy resulted in an absolute improve-
ment of 6.5% in 5-year overall survival for all patients but there
was no overall survival benefit for the addition of chemotherapy
to definitive radiotherapy in patients> 70 years of age (7).
Cetuximab, a humanized murine monoclonal antibody against
the epidermal growth factor receptor, has been shown to improve
overall survival over radiotherapy alone and is an attractive sys-
temic therapy in elderly patients that potentially avoids the oto-
and nephrotixicty as well as mucositis common to platinum-based
regiments used in head and neck cancer (8, 9). Similarly, stereotac-
tic body radiotherapy (SBRT) is an advanced radiation planning
and delivery technique that delivers a highly focused radiation dose
per fraction (≥6 Gy) in 1–5 fractions and is a well-established
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FIGURE 1 | Sample SBRT treatment plan. Case example for an 88-year-old
female with a T4aN0M0 squamous-cell carcinoma of the left buccal mucosa.
She received 44 Gy in five fractions prescribed to the 80% isodose line over
10 elapsed days using the TrueBeam® RapidArc™ platform and three
non-coplanar arcs. Dose–volume histogram shows the PTV (orange), oral
cavity (pink), mandible (yellow), spinal cord (chartreuse), and parotids (right
dark blue, left blue-green). She completed therapy with but grade 1 mucositis;
she later developed grade II oral ulceration and trismus. She remained NED
with complete metabolic response until dying from co-morbidities 20 months
following SBRT.
curative strategy for medical-inoperable early-stage lung can-
cers especially in elderly populations (10). SBRT± cetuximab has
emerged as a promising salvage strategy for unresectable locally
recurrent previously irradiated squamous-cell carcinomas of the
head and neck (11–14). When compared to conventionally frac-
tionated external beam radiotherapy, primary benefits of short
overall treatment time (five fractions over 1–2 weeks) and minimal
acute toxicity makes SBRT± cetuximab a potentially attractive
treatment strategy in elderly patients. We hypothesize that pri-
mary SBRT± cetuximab may provide a similarly effective local
therapy that minimizes acute toxicity and overall treatment time
for elderly patients with medically inoperable well-lateralized head
and neck cancers.
MATERIALS AND METHODS
Following Institutional Review Board approval, a retrospec-
tive review (2002–2013) identified 12 patients of advanced age
(median age 88 years) with medically inoperable head and neck
cancer treated with SBRT± cetuximab. Patients were selected for
a primary radiosurgical approach on a case-by-case basis at the
discretion of a multidisciplinary head and neck tumor board;
generally patients were selected based on a well-lateralized lesion
and concern for an inability to tolerate or patient refusal of conven-
tional treatment regimes. Following prior phase I dose-escalation
study in the re-irradiation setting, SBRT consisted primarily of
44 Gy in five fractions delivered on alternating days over 1–2 weeks
(see Figure 1) (13). Spinal cord doses was constrained to not
exceed 8–10 Gy (with cumulative maximum of 50 Gy for those
receiving prior radiotherapy), while the remaining normal tissues
be constrained as much as possible without compromising the tar-
get volume on a case-by-case determination. SBRT was delivered
via the CyberKnife®, Trilogy®, or TrueBeam® platforms with cus-
tom thermoplastic mask immobilization and daily image guidance
either via X-Sight® skull tracking, daily cone beam CT, or BrainLab
ExacTrac®. Early in our radiosurgery program, the gross tumor
volume (GTV) was equal to the planning target volume (PTV),
following a deformable registration analysis of the patterns of fail-
ure following SBRT; since 2012, we have employed a 2–5 mm GTV
to PTV expansion (15). Concurrent cetuximab was administered
at a dose of 400 mg/m2 on day -7 followed by 250 mg/m2 on day
0 and+7 in n= 3 (25%).
Patient-reported quality of life (PRQoL) was prospectively
recorded using the previously validated University of Washington
quality of life revised (UW-QoL-R) as part of an institutionally
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maintained database (16). UW-QoL-R measures QoL in 12
domains specific to head and neck cancer and three domains
of global health status using a single Likert-type question with
an assigned score of 0–100 (100 representing normal function).
UW-QoL-R surveys were administered at initial consultation and
each subsequent follow-up appointment, usually 1-month post-
irradiation then every 3 months. Mean scores and standard devi-
ations (SD) were calculated from UW-QoL-R and compared to
baseline values using the Wilcoxon signed-rank test. Toxicity was
physician record as per National Cancer Institute Common Ter-
minology Criteria for Adverse Events version 4.0 (CTCAE v4).
Survival and tumor control were estimated using the Kaplan Meier
method using SPSS Version 21 (SPSS, Chicago, IL, USA) calculated
from the time of SBRT to the date of failure or last follow-
up/death. Patients treated for palliative intent with metastatic
disease prior to radiosurgery were excluded for survival and
tumor control analysis, but were included for toxicity and QoL
assessments.
RESULTS
Baseline patient characteristics are outlined in Table 1. Briefly,
the median age at the time of radiosurgery was 88 years, with
57% female. The most common primary sites were oral cavity
(25%) and salivary gland/paranasal sinus (25%). Sixty-seven per-
cent were AJCC stage IVA, with a median treatment volume of
42.1 cc. Three patients (25%) were treated for local recurrence fol-
lowing initial surgery with no prior radiation therapy. No patients
completed prior (full dose) definitive chemoradiation; however,
two patients (17%) terminated conventional external beam radio-
therapy+ cetuximab after 12 and 30 Gy. The interval between con-
ventional external beam radiotherapy and SBRT for these patients
was 1 month and 2 years. Ninety-two percent completed the pre-
scribed course without major treatment interruption, with one
patient (8%) terminating treatment after four of a planned five
fractions due to declining performance status.
Median clinical follow-up was 6 months (range: 0.5–
29 months). The median time to death or last follow-up
was 16 months (range: 1–33 months). The 1-year actuarial
local progression-free survival, distant progression-free survival,
progression-free survival, and overall survival for definitively
treated patients were 69, 100, 69, and 64%, respectively. Specifics
for follow-up and treatment outcomes of the definitively treated
cohort are outlined in Table 2. Briefly, of the two patients who
experienced a local failure: one was infield and one was an over-
lap failure. No patients experience isolated neck failure. Of patients
who received definitive SBRT, at time of last follow-up, three (30%)
were alive without disease, two died with disease (20%), four died
without disease recurrence (40%), one (10%) underwent salvage
laryngectomy for local recurrence but died of a second primary
mucosal melanoma. One patient (8%) experienced acute grade 3
dysphagia and one patient (8%) experienced late grade 3 mucosi-
tis; there were no grade 4–5 toxicities. The most common recorded
grade 2 toxicities (experienced by> 1 patient) were acute grade 2
mucositis (n= 3, 25%), late grade 2 mucosal ulceration (n= 3,
25%), and late grade 2 dysphagia (n= 2, 17%).
UW-QoL-R was administered in 92%; with 58% (n= 7) com-
pleting both pre- and post-SBRT UW-QoL-R surveys. Of patients
Table 1 | Baseline patient characteristics.
Baseline characteristics All patients (n=12)
Concurrent cetuximab
SBRT+ cetuximab 3 (25%)
SBRT alone 9 (75%)
Age (years), median (range) 88 (79–98)
Gender
Male 5 (42%)
Female 7 (58%)
Primary site
Larynx 1 (8%)
Nasopharynx 1 (8%)
Oropharynx 2 (17%)
Oral cavity 3 (25%)
Salivary gland/sinuses 3 (25%)
Other 2 (17%)
AJCC stage
III 2 (17%)
IVA 8 (67%)
IVC 2 (17%)
Tumor volume (cm3), median (range) 42.1 (15.1–247.9)
Treatment duration (days), median (range) 10 (1–15)
Palliative intent (M1 disease prior to SBRT) 2 (17%)
completing both pre- and post-SBRT UW-QoL-R, the median
number of surveys was 3 (range: 2–7 surveys) with a median
follow-up survey time of 3 months (range: 0–15 months). At time
of last survey, 71% denoted improved or stable overall QoL for the
last 7 days as compared to baseline. Over the period of follow-up,
there were no significant differences in any of the 12-assessed head
and neck specific domains or three domains of global health com-
paring UW-QoL-R means for patients surviving to 15 months to
baseline (see Figure 2).
DISCUSSION
The results presented here-in for a primary approach of
SBRT± cetuximab show the feasibility in an elderly population
with a median age of 88 years. The 1-year local progression-
free survival of 69% and overall survival of 64% are compa-
rable to (see Table 3) prior results published for hypofraction-
ated external beam radiotherapy (17–21). Severe toxicity rates
were low at 16% overall (8% acute and 8% late toxicity), and
92% of patients were able to complete the prescribed treat-
ment course without interruption or major complication. This
overall tolerability of SBRT was perhaps anecdotally best high-
lighted by the two patients who terminated conventional exter-
nal beam radiotherapy plus cetuximab but were able to com-
plete SBRT plus cetuximab without interruption. Additionally,
prospective collection of patient-report QoL as assessed by UW-
QoL-R was preserved. While there were generally negative trends
across domains (see Figure 2), comparing baseline to 15-month
values these trends did not reach statistical significance. More-
over, at time of last UW-QoL-R survey, the majority of patients
(71%) reported improved for stable overall QoL over the last
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Table 2 | Description of definitive treatments and outcomes.
Age Primary
location
Histology AJCC stage PTV (cc) SBRT total
dose (Gy)
Fractions (n) Cetuximab Local
progression
(type)
Overall
disease
status
Time to death
or last follow-up
(months)
81 Base of
tongue
SCC T4N0M0 26 44 5 Y N NED 27
91 Alveolar ridge SCC T4N1M0 104 35.2a 4a Y – DOD 1
86 Parapharnygeal
space
NR T3N0M0 40 25 5 N Y (overlap) DOD 22
97 Maxillary
sinus
Spindle cell T3N0M0 53 20 1 N N DWOD 33
98 Larynx SCC T4N0M0 74 44 5 N Y (infield,
salvaged
with laryn-
gectomy)
DWOD 29
88 Buccal
mucosa
SCC T4N0M0 26 44 5 N N DWOD 20
87 Parotid Acinic cell rT0N2aM0 15 36 6 N N DWOD 11
82 Base of
tongue
SCC rT2N0M0
(initial
T1N2aM0)
44 44 5 Y N DWOD 6
93 Maxillary
sinus
SCC T4N0M0 41 44 5 N N NED 5
79 Parotid Epithelial
neoplasm
T4N0M0 248 44 5 N N NED 3
aPatient terminated treatment after four fractions of a planned dose of 44 Gy in five fractions due to declining performance status.
NED: no evidence of disease; DOD: dead of disease; DWOD: died without evidence of disease progression; NR: not recorded; SCC: squamous-cell carcinoma.
FIGURE 2 | Mean PRQoL values from baseline to 15 months as assessed by UW-QoL-R. QoL: quality of life; No. at risk: number of patients at risk.
1 week; consistent with prior reports for QoL outcomes fol-
lowing SBRT for recurrent previously irradiated head and neck
cancers (22).
These results add to a growing yet limited body of prior pub-
lished data for primary SBRT for patient with medically inoperable
head and neck cancer. These series highlight the potential bene-
fits of a primary radiosurgical approach (see Table 4) vis-a-vis
short treatment time, minimal acute toxicity, and promising local
control plus overall survival (23, 24). The integration of cetuximab
with primary SBRT is unique to this series. Concurrent cetuximab
has been shown to improve progression-free and overall survival
when added to conventional fractionated external beam radia-
tion alone and improve outcomes in the recurrent setting when
combined with SBRT (11–14). Concurrent cetuximab was well
tolerated in conjunction with SBRT for the three patients in our
series. However, additional follow-up and data are necessary to
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Table 3 | Summary of results for hypofractionated conventional
external beam radiotherapy in locally advanced head and neck cancer.
n Dose PFS OS
(months) (months)
Porceddu et al. (17) 35 30 Gy in 5 fx 3.9 6.1
Das et al. (18) 33 40 Gy in 10 fx – 7
Corry et al. (19) 38 14 Gy in 4 fx 3.1 5.7
Al-mamgani et al. (20) 158 50 Gy in 15 fx 14 17
Agarwal et al. (21) 110 40 Gy in 16 fx 1-yr 55% –
Present study 10a SBRT 20–44 in 1–5 fx 6 15.5
aProgression-free and overall survival rates are only for the 10 definitely treated
patients.
Fx: fractions; n: number of patients; PFS: progression-free survival; OS: overall
survival; Gy: Gray; yr: year.
Table 4 | Summary of data for primary SBRT in elderly patients.
n Dose LC OS Toxicity
Grade 3+
Siddiqui
et al. (23)
10 18–48 Gy
in 1–8fx
1 yr 83% 1 yr 70% 1 G3
cataract,
1 G3 pain
Kawaguchi
et al. (24)
14 35–42 Gy
in 3–5fx
71.4%
crude
78.6%
crude
1 G3
osteonecro-
sis
Present
study
10a 20–44 Gy
in 1–5fx
1 yr 69% 1 yr 64% 1 G3
dysphagia,
1 G3
mucositis
aLocal control and survival rates are only for the 10 definitely treated patients.
Fx: fractions; n: number of patients; LC: local control; OS: overall survival; G3:
grade 3; Gy: Gray; yr: year.
better define the potential efficacy when combined with SBRT in
the primary setting.
This series is limited by retrospective design subject to inher-
ent biases, most notably patient selection, and small sample size.
While short overall follow-up limits assessment of late compli-
cations, this series is strengthened by the addition of prospective
collection of PRQoL outcomes. Further prospective studies should
evaluate the role of SBRT± cetuximab as a primary treatment for
patient with well-lateralized head and neck cancers that are poor
candidates for standard of care combined modality therapy.
CONCLUSION
Stereotactic body radiotherapy shows encouraging survival rate
and relatively low toxicity in a medically inoperable elderly
patients population with head and neck cancer. Treatment was
well tolerated in the majority of elderly patients, including
those receiving a combination of SBRT plus concurrent cetux-
imab. SBRT± cetuximab may provide an aggressive potentially
curative local therapy while preserving QoL worthy of further
investigation.
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